medRxiv preprint doi: https://doi.org/10.1101/2021.03.29.21254526; this version posted March 31, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

	perpetaty.
It is made available under a	CC-BY-NC-ND 4.0 International license .

1	Longitudinal experiences and impact of the COVID-19 pandemic among people with past or
2	current eating disorders in Sweden
3	
4	Andreas Birgegård ¹ *, Afrouz Abbaspour ¹ , Stina Borg ¹ , David Clinton ¹ , Emma Forsén
5	Mantilla ¹ , Jet D. Termorshuizen ^{1,2} , and Cynthia M. Bulik ^{1,3,4}
6	
7	¹ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,
8	Sweden
9	² Rivierduinen Eating Disorders Ursula, Leiden, The Netherlands
10	³ Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North
11	Carolina , USA
12	⁴ Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North
13	Carolina, USA
14	
15	* Corresponding author. Address: MEB, Karolinska Institutet, Nobels väg 12A, 171 77,
16	Stockholm, Sweden
17	Email: andreas.birgegard@ki.se
18	Phone: +46-70-4843309
19	
20	Running title: COVID-19 and eating disorders
21	
22	Acknowledgements: Dr Bulik acknowledges support from the Swedish Research Council
23	(Vetenskapsrådet, award: 538-2013-8864). The authors also thank Peter Lind for valuable
24	support with IT.
25	
26	
27	

28	Abstract
29	
30	Objective: To document the impact of the COVI-19 pandemic on the health and well-being
31	of individuals with past and current eating disorders in Sweden.
32	Method: We re-contacted participants from two previous Swedish studies who had a known
33	lifetime history of an eating disorder. Participants completed an online questionnaire about
34	their health and functioning at baseline early in the pandemic (Wave 1; N=982) and six
35	months later (Wave 2); N=646).
36	Results: Three important patterns emerged: 1) higher current eating disorder symptom levels
37	were associated with greater anxiety, worry, and pandemic-related eating disorder symptom
38	increase; 2) patterns were fairly stable across time, although a concerning number who
39	reported being symptom-free at Wave 1 reported re-emergence of symptoms at Wave 2; and
40	3) only a minority of participants with current eating disorders were in treatment, and of those
41	who were in treatment, many reported fewer treatment sessions than pre-pandemic and
42	decreased quality of care.
43	Conclusions: The COVID-19 pandemic is posing serious health challenges for individuals
44	with eating disorders, whether currently symptomatic or in remission. We encourage health
45	service providers and patient advocates to be alert to the needs of individuals with eating
46	disorders and to take active measures to ensure access to appropriate evidence-based care
47	both during and following the pandemic.
48	
49 50 51	Keywords: eating disorders, pandemic, COVID-19, social isolation, relapse
52	Significant Outcomes and Limitations:
53	• Individuals with eating disorders symptoms or current active disorder report higher
54	adverse impact of COVID-19 on their mental health
55	• Even individuals who were symptom-free early in the pandemic reported a resurgence
56	of eating disorder symptoms
57	• A large proportion of symptomatic individuals were not in treatment for their eating
58	disorder, services should be aware and access to evidence-based care should be
59	ensured across Sweden
60	• Limitations included the use of a convenience sample with atypical diagnostic
61	distribution, and a low initial response rate, possibly introducing bias and limiting
62	generalisability.

63

- 64 **Data Availability Statement:** Fully anonymized data are available from the corresponding
- 65 author upon request.

66

Introduction

67 Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic in March 2020 68 by the World Health Organization. In response, countries across the globe implemented 69 70 varyingly strict measures to limit the spread of the virus, balancing the impact of public health 71 measures on social isolation, disruption of daily routines, and economic factors. Besides the 72 direct and often prolonged impact of COVID-19 on physical and mental health,^{1,2} pandemic-73 related restrictions have also adversely affected mental health in the general population,³⁴ and 74 may worsen the symptoms in individuals with pre-existing psychiatric illnesses.⁵⁶ We surveyed a large sample of individuals with eating disorders (ED) in Sweden at two timepoints—Wave 75 76 1 (baseline early in the pandemic) and Wave 2 (six months later)—to document the impact of 77 the pandemic and public health measures taken to limit its transmission on individuals with 78 EDs.

79

80 Several studies emerged in the literature early suggesting that the pandemic is adversely impacting individuals with ED. Reports from around the world suggest that exposure to 81 triggering environments (e.g., having to spend more time in close quarters with family or 82 roommates), lack of social support, and the absence of structure to daily life are particularly 83 84 challenging for individuals with EDs.^{7,8} Individuals surveyed report increases in ED symptoms, anxiety, and stress as a result of the pandemic.^{9,10} In addition, disruption to clinical services in 85 many countries has impeded access to treatment and initially, virtual care was rated as less 86 satisfactory than typical face-to-face treatment.^{10,11} Evidence of exacerbation of ED symptoms 87 88 in individuals with an ED during the COVID-19 pandemic has been documented in studies from, for example, Spain¹², Australia¹³, Germany¹⁴, the United States, and the Netherlands.¹⁰ 89

90

Our primary aim was to characterize experiences of individuals with a current or past ED in Sweden during the COVID-19 pandemic using a longitudinal design with assessments at baseline (Wave 1) and after 6 months (Wave 2). Sweden-specific information is valuable as the country has had a unique response to COVID-19 public health management. We investigated changes in illness status over time, ED symptoms, anxiety, treatment availability, and COVID-19-related concerns. We also investigated baseline variables that were associated with deterioration or improvement of illness status over time. Our results provide valuable

98 information for patients and families, clinicians, and advocacy groups about needs of
99 individuals with EDs in Sweden and have the potential to guide care strategies and resource
100 planning during this and future pandemics.

- 101
- 102
- 103
- 104

Material and Methods

105 **Participants and procedure**

We contacted all participants from two previous large-scale ED studies in Sweden: the
Anorexia Nervosa Genetics Initiative (ANGI)¹⁵ and the Binge Eating Genetics Initiative
(BEGIN), who had given permission to be recontacted for future research. All participants

109 had lifetime history of an ED (and many had current ED). Although all ED presentations were

110 included, the majority of participants had anorexia nervosa (AN), given the nature of the

111 parent ANGI study. Although all participants had verified diagnoses from the parent studies,

112 for the purposes of this study, we used self-reported diagnosis and self-reported symptom

status. We sent 3,774 emails on May 27th (170 emails were undeliverable) and when we froze

first-wave data collection after six weeks, 982 individuals had responded (27%). The second

115 wave, sent only to those who had completed the Wave 1 survey, was administered between

116 December 22^{nd} 2020 and February 2^{nd} 2021, and 646 responded (66% of Wave 1). The study

117 methodology was approved by the Swedish Ethical Review Authority (Dnr 2020-04136).

118

119 Survey

120 The survey (see Supplement 1) was modelled after a survey used in the United States and the

- 121 Netherlands to study the impact of the pandemic on individuals with EDs (Termorshuizen et
- 122 al.¹⁰) that queried physical and mental well-being related to COVID-19 in the previous two

123 weeks. Participants provided data on age, sex, gender identity, diagnostic and treatment

status, exposure to COVID-19, and current situational circumstances (e.g., quarantined,

125 physical distancing). A Likert scale was used to measure level of concern about changes in

126 ED symptoms, frequency of symptoms, and worry related to COVID-19. The 7-item version

- 127 of the Generalised Anxiety Disorder Scale (GAD-7)¹⁶ assessed anxiety, with Cronbach's
- alpha of .91 at Wave 1 and .92 at Wave 2. We applied the ≥ 10 cutoff¹⁶ for possible
- 129 diagnosable generalised anxiety disorder to categorize participants. Free-text items invited
- 130 participants to share additional comments (qualitative analyses will be discussed elsewhere).

We defined three subgroups according to self-reported symptom status, with the question

131

133

132 Statistical analysis

- 134 "Which of the following statements best describes your experience?" and response options "I 135 have previously had an ED but am currently free of symptoms" (NoSx), "I have previously had an ED and still experience some symptoms" (Sx), and "I currently have an ED" (ED). 136 Statistics for each wave are based on the symptom grouping reported at that timepoint, 137 138 whereas longitudinal analyses (migration) are based on Wave 1 groupings. Distribution at 139 both time points and migration across symptom groups over time are shown in Figure 1. 140 141 We examined changes in each symptom status group over time and baseline predictors of 142 symptom deterioration or improvement using Welch's t-tests (due to imbalanced design) and 143 Cohen's d effect sizes, by comparing those who changed group over time with baseline group 144 peers who did not change. Three contrasts were possible based on statistical power: symptom 145 deterioration (NoSx \rightarrow NoSx vs. NoSx \rightarrow Sx), and two comparisons marked by symptom 146 improvement ($Sx \rightarrow Sx$ vs. $Sx \rightarrow NoSx$ and $ED \rightarrow ED$ vs. $ED \rightarrow Sx$). We selected baseline 147 predictors that captured ED symptoms, anxiety level (GAD-7), and items that captured 148 concerns about factors that might increase ED symptoms. 149 150 Attrition analyses compared Wave 2 responders with those who responded only at Wave 1 to 151 investigate representativeness of the longitudinal subsample, on anxiety, worry about 152 symptom increase, and ED symptoms-153 154 155 Results 156 157 Sample characteristics and distribution of ED symptom groups 158 The sample consisted of 98% biological females, and gender identity distribution was 97% 159 female, 2% male, and 1% non-binary or other. Self-reported previous or current ED diagnosis 160 distribution (participants could mark several response alternatives) was: anorexia nervosa 161 64%; bulimia nervosa 37%; binge-eating disorder 24%; and other specified feeding and eating 162 disorder 45%; with 12% other; and 1% responding "Don't know/prefer not to answer". Table 163 1 shows descriptive statistics for COVID-19-related exposure and preventive measures at
- 164 Wave 1 and Wave 2. No significant differences emerged between individuals who responded

165	to both waves of data collection and those who responded to Wave 1 only on any tested
166	baseline variables.
167	
168	{Insert Table 1 About Here}
169	
170	Figure 1 shows the distribution of the symptom groups NoSx, Sx, and ED at each time point.
171	Thirty-four percent had no ED symptoms, ~50% had lingering symptoms, and 16% reported a
172	current active ED at each time point. Although the percentages at each timepoint were very
173	similar, migration did occur. A full 23% of individuals transitioned from NoSx at Wave 1 to
174	Sx at Wave 2 (i.e., deterioration); 15% of individuals with Sx at baseline reported NoSx at
175	Wave 2 (i.e., improvement); and 21% of individuals with ED at Wave 1 reported Sx at Wave
176	2 (i.e., improvement). The majority of individuals, however, remained in the same symptom
177	category across time.
178	
179	{Insert Figure 1 About Here}
180	
181	
182	Anxiety and ED symptom variables by symptom status group
183	Table 2 reveals that individuals in all three symptoms groups were more likely to say that
184	their anxiety had increased since the end of 2019 at Wave 2 than at Wave 1. In most cases
185	across symptom groups and at both waves, participants were more likely to attribute their
186	increases in anxiety to COVID-19 (data not shown).
187	
188	{Insert Table 2 About Here}
189	
190	GAD-7 was strongly associated with symptom group, and patterns were similar across waves.
191	At both Wave 1 and Wave 2, 23% of the NoSx group, ~50% of the Sx group, and 79% (Wave
192	1) and 76% (Wave 2) of the ED group scored above the cut-off for GAD-7.
193	
194	{Insert Figure 2 About Here}
195	
196	
197	

198 Table 3 shows that concern about ED symptom increase due to the pandemic¹ was strongly 199 related to symptom status group. Participants in **ED** were more concerned about increased 200 symptoms due to lack of structure and social support, and being exposed to triggering 201 environments, than Sx, who in turn were more concerned than NoSx. Patterns were similar 202 across waves. 203 204 Table 3 further shows that more participants reported being worried about others being 205 infected by COVID-19 than themselves, and increased ED symptom level status was 206 associated with higher worry. Further, participants were much more worried about their 207 mental health being affected than physical health, and there was a clear pattern of higher ED 208 symptoms being associated with higher levels of concern. 209 210 {Insert Table 3 About Here} 211 212 A similar pattern emerged with ED symptoms, with increasing symptoms of binge eating, 213 restrictive eating, and compensatory behaviours across NoSx, Sx, and ED groups. Concern 214 about not being able to exercise was similar in both ED and Sx. Patterns were similar across 215 waves. 216 217 Treatment 218 Table 4 presents treatment-related results. Notably, the majority of individuals with active 219 EDs reported not being in current treatment. Most notably, a majority had no current ED 220 treatment, 40% had had fewer sessions in the last two weeks, and a substantial proportion 221 experienced their treatment quality as worse or much worse than before the pandemic. On the other hand, fairly many still had face-to-face sessions and a majority experienced their 222 223 treatment as good or better than before the pandemic. 224 225 **Migration between symptom status groups** 226 We conducted two analyses exploring Wave 1 predictors of a change in symptom status 227 between Wave 1 and Wave 2 (Table 5). Two analyses investigated factors associated with

²²⁸ deterioration and two related to improvement.

¹ Some response options in this item ("concern", see Supplement 1) are not shown since scores were very low as the response options are relatively irrelevant for Swedish conditions; these related to concern about not being able to afford food or treatment, which is not an issue in Sweden at this point.

229	Those individuals who transitioned from NoSx to Sx had significantly higher Wave 1 mean
230	GAD-7 scores, greater concern about being in a triggering environment, and higher worry
230	about not being able to exercise, with medium effect sizes. They also had significantly higher
232	concern about lack of structure and social support, but with small effect sizes.
233	Individuals who transitioned from Sx at Wave 1 to No Sx at Wave 2 had lower scores on
234	concerns about lack of structure, social support, and being in a triggering environment and
235	lower scores on compensatory behaviours, with small to medium effects. Individuals who
236	moved from ED at Wave 1 to Sx at Wave 2 had lower baseline GAD-7 scores.
237	
238	{Insert Tables 4 and 5 About Here}
239	
240	Discussion
241	
242	We characterized experiences of people with a current or past ED early in the COVID-19
243	pandemic and six months later. Using a survey coordinated with studies in the USA and the
244	Netherlands, we identified three important patterns. First, the higher the current ED symptom
245	level of the participant, the more anxiety, worry, and ED symptom increase was reported.
246	Second, results were fairly stable across time, with some exceptions. Third, quite
247	concerningly, only a minority of participants with current ED were in treatment, and of those
248	who were in treatment many reported fewer treatment sessions than usual and decreased
249	quality of care.
250	
251	The overall impression is that among people with experience of an ED, those with
252	lingering symptoms or current active disorder are particularly vulnerable to the disruptions
253	and anxiety caused by the COVID-19 pandemic and the societal restrictions that have
254	necessarily been put in place. GAD-7 results suggested that a full three-quarters of individuals
255	with active EDs were likely to also have generalised anxiety disorder. In the absence of pre-
256	pandemic data, we are unable to determine whether this is higher than would be expected, but
257	regardless it reflects the importance of attending to anxiety in the treatment of individuals
258	with EDs during the pandemic. Although we found relatively few relapses into ED, a
259	concerning number who initially reported being symptom-free reported re-emergence of
260	symptoms as the pandemic progressed.
260	of infronte at the funderine profilested.

261

262 Regarding predictors of deteriorating symptoms, baseline anxiety, weaker social support 263 and structure, and fears about not being able to exercise were all associated with worsening 264 ED symptoms. Symptom improvement showed to some extent the opposite pattern, as it was 265 associated with lower anxiety and higher ratings on social support and structure. These results 266 may be especially informative for treatment planning and safeguarding continued recovery, 267 since they underscore the importance of ensuring that individuals with current or past EDs 268 have skills to address anxiety and strategies to forge social connectedness as well as support 269 and adequate structure to their daily lives.

270

271 Intriguingly, our results closely mirror results reported in the US and the Netherlands,¹⁰ 272 suggesting that despite considerable differences in the public health measures used across the 273 three countries to contain transmission of COVID-19, the impact on individuals with EDs was 274 comparable. Indeed, EDs thrive in social isolation with patients reporting feeling alone with 275 their ED thoughts and isolated in terms of monitoring their weight and eating. Since 276 developing regular and adequate eating is central to ED recovery and maintenance of 277 treatment gains, the absence of a predictable daily structure removes a central component of 278 ED care.

279

280 Our results have direct clinical implications for clinicians working with ED patients during the pandemic as well as for advocacy organizations who provide additional support. 281 282 Even if patients have been transitioned to virtual care, it is important to ensure that they have 283 adequate social support via families, peers, advocacy organizations, or even online forums to 284 maintain accountability and motivation for recovery. It is also essential to assess directly 285 individuals' living arrangements. Given limitations on socializing and recommendations for 286 physical distancing during the pandemic, individuals may find themselves with less freedom 287 and flexibility to extricate themselves from unhelpful or even toxic environments. Remaining 288 vigilant for triggering situations and providing practical assistance with managing them is of 289 critical import. Finally, assisting patients with developing and maintaining structure to their 290 daily lives, especially when working from home, can aid recovery. Providing support, social 291 connectedness, and daily structure are three clinical targets that appear to be critical to ED 292 patients during the pandemic.

293

Although our study provides important knowledge about how individuals with ED are coping with the pandemic, it has several limitations. First, given our intention to field a survey

296 soon after COVID-19 was declared a global pandemic, we rapidly translated and adapted a 297 survey used in the US and the Netherlands. This precluded typical steps to ensure sound 298 psychometric properties. Second, we relied on a convenience sample (i.e., individuals who 299 had participated in previous studies who agreed to be contacted for future research), which 300 did not reflect the distribution of diagnoses to be expected from a community sample and may 301 have biased results. Third, we relied on self-report diagnosis and symptom reports to characterize patients. Although all participants had formal diagnoses in the past, the use of 302 303 self-reports to establish current status remains a limitation. Fourth, our response rate to the 304 initial survey was low (27%) and we experienced attrition between the waves, again 305 potentially introducing bias and limiting generalisability. Finally, we were underpowered for 306 some analyses; group sizes were low for analysing transitions between symptom levels across 307 time.

308

309 Nevertheless, we were able to capture fairly early on in the pandemic how individuals 310 with ED were being affected. As anticipated, COVID-19 has been particularly challenging for 311 those with existing active mental disorders, and even those who are currently symptom-free 312 are challenged to remain healthy. We encourage clinicians and advocacy organizations to 313 avail themselves of these results to aid in developing resources for patients, families, and 314 clinicians for dealing with ED during the pandemic. Given the frequency with which individuals with active EDs reported not being in treatment and the concerning number who 315 316 initially reported being symptom-free who subsequently reported re-emergence of symptoms six months later, we encourage health service providers and patient advocates to be alert to 317 318 the needs of ED patients and to take active measures to ensure access to appropriate evidence-319 based care for all EDs across Sweden during the pandemic and subsequently when there may 320 be a serious backlog of individuals requiring care.

321

322		References
323	1.	Butler M, Pollak TA, Rooney AG, Michael BD, Nicholson TR. Neuropsychiatric
324		complications of covid-19. <i>The BMJ</i> . 2020;371. doi:10.1136/bmj.m3871
325	2.	Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19.
326		JAMA - Journal of the American Medical Association. 2020;324(6).
327		doi:10.1001/jama.2020.12603
328	3.	The Lancet Psychiatry. Mental health and COVID-19: change the conversation. <i>The</i>
329		<i>Lancet Psychiatry</i> . Published online 2020. doi:10.1016/S2215-0366(20)30194-2
330	4.	Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in
331		the general population: A systematic review. <i>Journal of Affective Disorders</i> . 2020;277.
332		doi:10.1016/j.jad.2020.08.001
333	5.	Gobbi S, Płomecka MB, Ashraf Z, et al. Worsening of Preexisting Psychiatric
334		Conditions During the COVID-19 Pandemic. Frontiers in Psychiatry. 2020;11.
335		doi:10.3389/fpsyt.2020.581426
336	6.	Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric
337		symptoms during COVID-19 pandemic and lockdown? A case-control study with
338		service and research implications for immunopsychiatry. Brain, Behavior, and
339		Immunity. 2020;87. doi:10.1016/j.bbi.2020.04.069
340	7.	Geller J, Iyar M, Srikameswaran S, Zelichowska J, Dunn EC. Social support
341		satisfaction in adults with eating disorders: Does stance matter? International Journal
342		of Eating Disorders. 2017;50(7). doi:10.1002/eat.22695
343	8.	Lindstedt K, Neander K, Kjellin L, Gustafsson SA. Being me and being us -
344		Adolescents' experiences of treatment for eating disorders. Journal of Eating
345		Disorders. 2015;3(1). doi:10.1186/s40337-015-0051-5
346	9.	Chan CY, Chiu CY. Disordered eating behaviors and psychological health during the
347		COVID-19 pandemic. Psychology, Health & Medicine. Published online 2021.
348		doi:10.1080/13548506.2021.1883687
349	10.	Termorshuizen JD, Watson HJ, Thornton LM, et al. Early impact of COVID-19 on
350		individuals with self-reported eating disorders: A survey of ~1,000 individuals in the
351		United States and the Netherlands. International Journal of Eating Disorders.
352		2020;53(11). doi:10.1002/eat.23353
353	11.	Weissman RS, Bauer S, Thomas JJ. Access to evidence-based care for eating
354		disorders during the COVID-19 crisis. International Journal of Eating Disorders.
355		2020;53(5). doi:10.1002/eat.23279

356	12.	Fernández-Aranda F, Casas M, Claes L, et al. COVID-19 and implications for eating
357		disorders. European Eating Disorders Review. Published online 2020.
358		doi:10.1002/erv.2738
359	13.	Phillipou A, Meyer D, Neill E, et al. Eating and exercise behaviors in eating disorders
360		and the general population during the COVID-19 pandemic in Australia: Initial results
361		from the COLLATE project. International Journal of Eating Disorders. 2020;53(7).
362		doi:10.1002/eat.23317
363	14.	Schlegl S, Maier J, Meule A, Voderholzer U. Eating disorders in times of the
364		COVID-19 pandemic—Results from an online survey of patients with anorexia
365		nervosa. International Journal of Eating Disorders. 2020;53(11).
366		doi:10.1002/eat.23374
367	15.	Thornton LM, Munn-Chernoff MA, Baker JH, et al. The Anorexia Nervosa Genetics
368		Initiative (ANGI): Overview and methods. Contemporary Clinical Trials. 2018;74.
369		doi:10.1016/j.cct.2018.09.015
370	16.	Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing
371		generalized anxiety disorder: The GAD-7. Archives of Internal Medicine.
372		2006;166(10). doi:10.1001/archinte.166.10.1092
373		
374		

Table 1.

COVID-19 exposure and preventive measures; % "Yes" responses (See Supplement for full questionnaire)

Item	Wave 1 <i>n</i> (%)	Wave 2 <i>n</i> (%)
Practicing social distancing	749 (77%)	556 (87%)
Forced isolation	10 (1%)	3 (1%)
Work/study from home	457 (47%)	341 (53%)
Ordered home stay	51 (5%)	37 (6%)
Tested positive for COVID-19	17 (2%)	56 (9%)
Clinical COVID-19 diagnosis	6 (1%)	4 (1%)
Have not had COVID-19	618 (63%)	443 (69%)
Maybe had COVID-19 but not sure	336 (34%)	139 (22%)

Table 2.Changes in self-reported anxiety by symptom group.

Item	Group						
		"No cha	nge"	"Increas	ed"	"Decrease	ed"
Anxiety level		Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2
changed since the end of 2019?	NoSx	48%	43%	34%	41%	17%	17%
ena 0j 2019?	Sx	35%	29%	51%	54%	14%	17%
	ED	33%	20%	58%	67%	10%	14%

Note: NoSx=No ED symptoms; Sx=Some remaining symptoms; ED=Current eating disorder

Table 3.

Worry about impact of COVID-19 by symptom group and measurement wave for items related to concern about factors leading to increased ED symptoms, ED symptoms themselves, and worry about the impact of COVID-19 on others and own health. See Supplement for items.

Variable	Response options shown	Symptom group	Wave 1	Wave 2
Worry that ED symptoms	Per cent responding	NoSx	10%	7%
increase due to lack of structure	"Fairly worried" to	Sx	33%	31%
	"Very worried"	ED	56%	61%
Worry that ED symptoms		NoSx	3%	4%
increase due to lack of social		Sx	20%	19%
support		ED	51%	48%
Worry that ED symptoms		NoSx	9%	6%
increase due to being in a		Sx	32%	32%
triggering environment		ED	56%	53%
Binge eating bunkered food	Per cent responding	NoSx	1%	1%
Binge eating bunkered lood	"Often" to "Daily or	Sx	8%	7%
	more"	ED	24%	23%
	more			
Restricted food intake due to		NoSx	5%	2%
COVID-19-related factors		Sx	14%	11%
		ED	27%	24%
Compensated for food intake		NoSx	1%	1%
food intake due to COVID-19-		Sx	9%	8%
related factors		ED	26%	28%
Worried about not being able to		NoSx	17%	18%
exercise		Sx	36%	37%
		ED	39%	46%
Worry about self being infected	Per cent responding	NoSx	23%	39%
wony about sen being infected	"Fairly worried" to	Sx	28%	38%
	"Very worried"	ED	32%	40%
Worry about others being		NoSx	79%	79%
infected		Sx	78%	84%
		ED	80%	86%
Worry about physical health		NoSx	28%	39%
being affected		Sx	37%	50%
-		ED	45%	54%
Worry about mental health being		NoSx	42%	50%
affected		Sx	59%	65%
		ED	65%	73%

Note: NoSx=No ED symptoms; Sx=Some remaining symptoms; ED=Current eating disorder

	÷,
	Ē
	neriences o
	- u
4	- E
ble	- e
Table	×
r ,	<u> </u>

	" encione H(H)	ione"	"Tvanciti	"Transition of to wistual"	"on coscions"	10 mc 2	"(Not in troatment")	atmont"
		6101	marcalan I T			6110		
Presence and	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2
format of treatment	27%	28%	10%	9%	7%	13%	58%	51%
	"Fewer sessions"	ssions"	(uom sk."	"As many sessions"	"More sessions"	ssions"		
Change in session	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2		
Jrequency	40%	41%	53%	54%	7%	5%		
	"Better"		"As good"	•	"A little worse"	vorse"	"Much worse	ırse
Change in ED	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2
treatment quality	4%	5%	56%	49%	29%	30%	11%	16%

2). Responses in the past two weeks (Wave 1 n=55, Wave 2 n=37).

Compared	GAD-7	Worry about	Concern about	Concern	Concern	Binge	Restrictive	Compensatory	Worry about no
groups		mental health being affected	lack of structure	about lack of social support	about triggering	eating	eating)	symptoms (e.g. vomiting)	exercise
					environment				
	M(SD)	M(SD)	M(SD)	M(SD)	M(SD)	M(SD)	M(SD)	M(SD)	M(SD)
Stable NoSv	6.0(4.24) ***· ++	1.7 (.78)	1.4 (.68) * · +	1.2 (.42) * - +	1.3 (.58) ** · ++	1.1 (.27)	1.2 (.52)	1.1 (.30)	1.6(.83) ** · ++
vs. VoSx →Sx	9.2 (5.60)	1.8 (.67)	, 1.7 (.88)	, 1.4 (.64)	, 11 1.8 (1.02)	1.2 (.43)	1.3 (.68)	1.1 (.35)	2.1 (1.04)
Stable Sx	10.2 (5.43)	1.8 (.68)	2.2 (.97) ** · *	1.8(.96) ** · +	2.1 (1.02) * - *	1.4 (.64)	1.5 (.76)	1.4(.65)	2.1 (1.09)
sy Sx →NoSx	9.4 (5.62)	1.8 (.64)	, 1.8 (.84)	, 1 1.4 (.69)	, 1 1.7 (.92)	1.3 (.64)	1.5 (.76)	, 1 1.2 (.46)	2.0 (1.02)
Stable ED	14.5(4.95) * · **	1.8 (.58)	2.7 (1.13)	2.6 (1.13)	2.6 (1.07)	1.6 (.94)	1.7 (.94)	1.7 (.96)	2.1 (1.11)
$ED \rightarrow Sx$, 11 11.6 (4.98) 1.6 (.66)	1.6 (.66)	2.6 (1.23)	2.4 (1.11)	3.0 (1.07)	2.0 (1.04)	1.5 (.73)	1.7 (.94)	2.3 (1.02)

Table 5.

Figure Legends.

Figure 1. Distribution (n, %) of participants into self-reported symptom-level groups at each measurement wave, where NoSx=previous ED but no current symptoms, Sx=previous ED and remaining symptoms, and ED=current ED. Circle sizes approximate group size, and migration between groups (arrows) is displayed with percentage of starting group moving to another.

Figure 2. Proportion of individuals scoring above/below the GAD-7 cut-off (≥ 10) at each time wave, separated by ED status group.




Figure 1.




Figure 2.